Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Greer

Showing results (161-170 of 178) with videos related to

Pageof 18
Sort By:
Brain Research|November 24, 1998
Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correctionC C Meltzer, G Smith, J C Price, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 26, 2016
Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 SignalingRomany A N Johnpulle, Sophie Paczesny, Dae Kwang Jung, et al.
Haematologica|January 29, 2016
Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantationBrian G Engelhardt, Sophie Paczesny, Dae Kwang Jung, et al.
Leukemia & Lymphoma|September 6, 2007
High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomesBrian G Engelhardt, Derek W Holland, Stephen J Brandt, et al.
Leukemia & Lymphoma|June 12, 2019
Clinicopathologic correlates of <i>MYD88</i> L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphomaTarsheen K Sethi, Alexandra E Kovach, Natalie S Grover, et al.
Leukemia & Lymphoma|October 8, 1999
Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant GroupD R Fleming, S N Wolff, J W Fay, et al.
Bone Marrow Transplantation|April 4, 2000
Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemiaZ S Pavletic, E R Arrowsmith, P J Bierman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2012
Prevention and treatment of cancer-related infectionsLindsey Robert Baden, William Bensinger, Michael Angarone, et al.
Acta Haematologica|July 18, 2019
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE RegistryFrederick Lansigan, Steven M Horwitz, Lauren C Pinter-Brown, et al.
Blood Advances|February 11, 2026
ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALLKristen M O'Dwyer, Lena E Winestone, Matthew C Cheung, et al.
Pageof 18

Showing results (161-170 of 178) with videos related to

Sort By:
Pageof 18
Brain Research|November 24, 1998
Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correctionC C Meltzer, G Smith, J C Price, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 26, 2016
Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 SignalingRomany A N Johnpulle, Sophie Paczesny, Dae Kwang Jung, et al.
Haematologica|January 29, 2016
Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantationBrian G Engelhardt, Sophie Paczesny, Dae Kwang Jung, et al.
Leukemia & Lymphoma|September 6, 2007
High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomesBrian G Engelhardt, Derek W Holland, Stephen J Brandt, et al.
Leukemia & Lymphoma|June 12, 2019
Clinicopathologic correlates of <i>MYD88</i> L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphomaTarsheen K Sethi, Alexandra E Kovach, Natalie S Grover, et al.
Leukemia & Lymphoma|October 8, 1999
Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant GroupD R Fleming, S N Wolff, J W Fay, et al.
Bone Marrow Transplantation|April 4, 2000
Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemiaZ S Pavletic, E R Arrowsmith, P J Bierman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2012
Prevention and treatment of cancer-related infectionsLindsey Robert Baden, William Bensinger, Michael Angarone, et al.
Acta Haematologica|July 18, 2019
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE RegistryFrederick Lansigan, Steven M Horwitz, Lauren C Pinter-Brown, et al.
Blood Advances|February 11, 2026
ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALLKristen M O'Dwyer, Lena E Winestone, Matthew C Cheung, et al.
Pageof 18